Putting Science to Work

In the News

Syngene International Jumps 32% From Issue Price Within One Quarter

CNBC TV18- 15/09/2015. "Syngene International is targeting a growth of USD 250 million by FY2018", says Peter Bains CEO of the company) .

Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget